Rockefeller Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BDTX
Rockefeller Capital Management's BDTX Position: Q3 2026 in Review
Rockefeller Capital Management held its Black Diamond Therapeutics (BDTX) position steady in Q3 2026 at 200 shares worth $377. The position accounts for ﹤0.01% of the portfolio, ranked #4758.
Rockefeller Capital Management first reported a position in BDTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $758 in Q3 2025. 111 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.
- Rockefeller Capital Management held 200 shares of Black Diamond Therapeutics worth $377 as of Q3 2026.
- Rockefeller Capital Management left its Black Diamond Therapeutics share count unchanged in Q3 2026.
- Black Diamond Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4758 holding.
- Rockefeller Capital Management first reported a position in Black Diamond Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Rockefeller Capital Management's Black Diamond Therapeutics position peaked at $758 in Q3 2025.
- 111 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.